Form 4: Acadia Pharmaceuticals Director Edmund Harrigan Reports Significant Equity Transactions

Acadia Pharmaceuticals Inc. Director Edmund Harrigan reported the vesting of restricted stock units and the acquisition of new stock options and restricted stock units on May 29, 2025, increasing his direct beneficial ownership of common stock to 35,041 shares.

Summary

• Edmund Harrigan, a Director at Acadia Pharmaceuticals Inc. (ACAD), reported equity transactions on May 29, 2025.
• He acquired 9,387 shares of common stock through the exercise/conversion of derivative securities.
• Following this transaction, his direct beneficial ownership of common stock stands at 35,041 shares.
• 9,387 Restricted Stock Units (RSUs) vested in full on May 29, 2025, which was the date of an annual meeting of stockholders.
• He was granted 13,793 Director Stock Options with an exercise price of $22.29, which will vest quarterly over one year, with the final tranche vesting on the earlier of one year following the grant date or the next annual meeting of stockholders.
• He was also granted 8,107 Restricted Stock Units, which will vest in full on the earlier of one year following the grant date or the next annual meeting of stockholders.

Sentiment

Score: 7

Explanation: The filing indicates a director's continued equity participation and increased beneficial ownership, which is generally viewed positively as it aligns management interests with shareholders. The transactions are routine compensation events.

Positives

• Director Edmund Harrigan increased his direct beneficial ownership of common stock to 35,041 shares, indicating continued alignment with shareholder interests.
• The vesting of 9,387 Restricted Stock Units demonstrates the realization of previously granted equity compensation.
• The grant of new stock options (13,793) and Restricted Stock Units (8,107) provides ongoing incentives for the director.

Future Outlook

NA

Industry Context

This Form 4 filing details routine equity compensation and insider ownership changes for a director at Acadia Pharmaceuticals, a biopharmaceutical company. Such filings are standard disclosures and do not typically reflect broader industry trends, but rather individual executive compensation and alignment with company performance.

Stakeholder Impact

• Shareholders: The increase in direct beneficial ownership by a director aligns management's interests with shareholders, potentially signaling confidence in the company's future performance.

Next Steps

• The newly granted stock options and restricted stock units will vest over time, with specific vesting schedules tied to future dates or the next annual meeting of stockholders.

Key Dates

Recommendation

Keywords

Acadia Pharmaceuticals, ACAD, Form 4, Insider Transaction, Edmund Harrigan, Director, Stock Options, Restricted Stock Units, Equity Compensation, Beneficial Ownership